Functional analysis of sites within PCSK9 responsible for hypercholesterolemia

Journal of Lipid Research

Volumn 49, Issue 6, 2008, Pages 1333-1343

  Pandit, Shilpa ^a   Wisniewski, Doug ^a   Santoro, Joseph C ^a   Ha, Sookhee ^a   Ramakrishnan, Vijayalakshmi ^a   Cubbon, Rose M ^a   Cummings, Richard T ^a   Wright, Samuel D ^a   Sparrow, Carl P ^a   Sitlani, Ayesha ^a   Fisher, Timothy S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

LDL; LDL receptor; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ASPARTIC ACID; LOW DENSITY LIPOPROTEIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE; SERINE PROTEINASE; UNCLASSIFIED DRUG; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN, HUMAN; PRIMER DNA;

ARTICLE; EMBRYO; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MUTAGENESIS; MUTANT; MUTATION; PRIORITY JOURNAL; PROTEIN INTAKE; PROTEIN STABILITY; WILD TYPE; CELL LINE; CHEMISTRY; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ASPARTIC ACID; BASE SEQUENCE; CELL LINE; DNA PRIMERS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MUTAGENESIS; RECEPTORS, LDL; SERINE; SERINE ENDOPEPTIDASES;

EID: 48549087567     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800049-JLR200     Document Type: Article

References (36)

1. Soutar, A. K., and R. P. Naoumova. 2007. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 4: 214-225.
2. Abifadel, M., M. Varret, J-P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34: 154-156.
3. Leren, T. 2004. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin. Genet. 65: 419-422.
4. Timms, K. M., S. Wagner, M. Samuels, K. Forbey, H. Goldfine, S. Jammulapati, M. Skolnick, P. Hopkins, S. Hunt, and D. Shattuck. 2004. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114: 349-353.
5. Homer, V. M., A. D. Marais, F. Charlton, A. D. Laurie, N. Hurndell, R. Scott, F. Mangili, D. R. Sullivan, P. J. Barter, K. A. Rye, et al. 2007. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis. 196: 659-666.
6. Bourbon, M., A. C. Alves, A. M. Medeiros, S. Silva, A. K. Soutar, and Investigators of Portuguese FH Study. 2007. Familial hypercholesterolaemia in Portugal. Atherosclerosis. 196: 633-642.
7. Cohen, J., A. Pertsemlidis, I. K. Kotowski, R. Graham, C. K. Garcia, and H. H. Hobbs. 2005. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37: 161-165.
8. Berge, K. E., L. Ose, and T. P. Leren. 2006. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 26: 1094-1100.
9. Kotowski, I., A. Pertsemlidis, A. Luke, R. S. Cooper, G. L. Vega, J. C. Cohen, and H. H. Hobbs. 2006. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78: 410-422.
10. Zhao, Z., Y. Tuakli-Wosornu, T. A. Lagace, L. Kinch, N. V. Grishin, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79: 514-523.
11. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y-A. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA. 102: 5374-5379.
12. Seidah, N. G., and M. Chretien. 1999. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res. 848: 45-62. (Pubitemid 30001653)
13. Seidah, N. G., S. Benjannet, L. Wickham, J. Marcinkiewicz, S. B. Jasmin, S. Stifani, A. Basak, A. Prat, and M. Chretien. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA. 100: 928-933.
14. Steiner, D. F. 1998. The proprotein convertases. Curr. Opin. Chem. Biol. 2: 31-39.
15. Naureckiene, S., L. Ma, K. Sreekumar, U. Purandare, C. F. Lo, Y. Huang, L.W. Chiang, J.M. Grenier, B. A. Ozenberger, J. S. Jacobsen, et al. 2003. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys. 420: 55-67.
16. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M-C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279: 48865-48875.
17. Cunningham, D., D. E. Danley, K. F. Geoghegan, M. C. Griffor, J. L. Hawkins, T. A. Subashi, A. H. Varghese, M. J. Ammirati, J. S. Culp, L. R. Hoth, et al. 2007. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14: 413-419.
18. Piper, D. E., S. Jackson, Q. Liu, W. G. Romanow, S. Shetterly, S. T. Thibault, B. Shan, and N. P. C. Walker. 2007. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure. 15: 545-552. (Pubitemid 46702689)
19. Hampton, E. N., M. W. Knuth, J. Li, J. L. Harris, S. A. Lesley, and G. Spraggon. 2007. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc. Natl. Acad. Sci. USA. 104: 14604-14609.
20. Lagace, T. A., D. E. Curtis, R. Garuti, M. C. McNutt, S. W. Park, H. B. Prather, N. N. Anderson, Y. K. Ho, R. E. Hammer, and J. D. Horton. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116: 2995-3005.
21. Fisher, T. S., P. Lo Surdo, S. Pandit, M. Mattu, J. C. Santoro, D. Wisniewski, R. T. Cummings, A. Calzetta, R. M. Cubbon, P. A. Fischer, et al. 2007. PCSK9-dependent LDL receptor regulation: effects of pH and LDL. J. Biol. Chem. 282: 20502-20512.
22. Qian, Y-W., R. J. Schmidt, Y. Zhang, S. Chu, A. Lin, H. Wang, X. Wang, T. P. Beyer, W. R. Bensch, W. Li, et al. 2007. Secreted proprotein convertase subtilisin/kexin-type 9 downregulates low-density lipoprotein receptor through receptor-mediated endocytosis. J. Lipid Res. 48: 1488-1498.
23. Li, J., C. Tumanut, J-A. Gavigan, W-J. Huang, E. N. Hampton, R. Tumanut, K. F. Suen, J. W. Trauger, G. Spraggon, S. A. Lesley, et al. 2007. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem. J. 406: 203-207. (Pubitemid 47310950)
24. McNutt, M. C., T. A. Lagace, and J. D. Horton. 2007. Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells. J. Biol. Chem. 282: 561-568.
25. Nassoury, N., D. A. Blasiole, A. Tebon Oler, S. Benjannet, J. Hamelin, V. Poupon, P. S. McPherson, A. D. Attie, A. Prat, and N. G. Seidah. 2007. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 8: 718-732. (Pubitemid 46785153)
26. Zhang, D-W., T. A. Lagace, R. Garuti, Z. Zhao, M. McDonald, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2007. Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282: 18602-18612.
27. Mathis, G. 1993. Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin. Chem. 39: 1953-1959.
28. Mathis, G. 1995. Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin. Chem. 41: 1391-1397.
29. Oldfield, T. J. 1996. Crystallographic Computing 7. P. E. B. K. D. Waterpaugh, editor. Oxford University Press, Oxford, UK.
30. Kearsley, S. K., D. J. Underwood, R. P. Sheridan, and M. D. Miller. 1994. Flexibases: a way to enhance the use of molecular docking methods. J. Comput. Aided Mol. Des. 8: 565-582.
31. Thomas, A. H. 1999. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 20: 730-748.
32. Park, S. W., Y-A. Moon, and J. D. Horton. 2004. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279: 50630-50638.
33. Cameron, J., O. L. Holla, T. Ranheim, M. A. Kulseth, K. E. Berge, and T. P. Leren. 2006. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 15: 1551-1558.
34. Ding, K., S. J. McDonough, and I. J. Kullo. 2007. Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species. PLoS ONE. 2: e1098.
35. Benjannet, S., D. Rhainds, J. Hamelin, N. Nassoury, and N. G. Seidah. 2006. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J. Biol. Chem. 281: 30561-30572.
36. Kwon, H. J., T. A. Lagace, M. C. McNutt, J. D. Horton, and J. Deisenhofer. 2008. Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. USA. 105: 1820-1825.